Deadweight loss is the value of trades that never happen because a monopolist restricts output to hold prices up. Unlike the transfer from buyers to the seller, which stays in someone's pocket, deadweight loss is pure waste: both sides would have gained from the trade, and nobody captures anything. The same logic applies to cartels, taxes, price controls, and tariffs.
On this page
In 2018, the list price for a course of Daraprim, an anti-parasitic drug that costs roughly $1 to manufacture per pill, stood at $750 per tablet in the United States.1 Most patients would clearly pay something far above that $1 cost to access treatment they needed. The manufacturer, holding exclusive rights to the formulation, priced so high that thousands of prescriptions were simply never filled. No money changed hands on those transactions. No one captured anything. The value of relief that would have benefited both buyer and seller just evaporated.
That vanished value has a name in economics: deadweight loss. It is the most important cost of monopoly precisely because it is invisible. It never appears as a line item, a loss, or a transfer anywhere. It is the cost of trades that never happen.
Why this is different from what you think monopoly costs
Most people picture the harm of monopoly as the extra money customers hand over. That part is real, but economists call it a transfer: it moves from buyers' pockets to the monopolist's, and the dollars still exist somewhere. Deadweight loss is different and more troubling. Nobody gains it. It is pure waste.
The clearest way to see this is through two ideas. Consumer surplus is the gap between what a buyer would have paid and what they actually paid: the patient who valued the pill at $30 and got it for $4 captured $26 of surplus. Producer surplus is the gap between the price a seller receives and the lowest price they would have accepted. In a competitive market, output expands until price equals marginal cost, and every trade where a buyer values the good above its cost gets made. Total surplus, the combined value to society, is maximized. As the Library of Economics and Liberty explains in its treatment of monopoly, the case against a monopolist rests not on the transfer to the seller but on this lost output: the trades that vanish when a firm restricts supply to hold its price up.2
Let me say what this really means. When a transaction never happens, the willingness to pay sits idle on one side and the productive capacity sits idle on the other. Both parties would have come out ahead. The market just failed to bring them together, because the seller found it more profitable to serve fewer people at a higher price.
How the loss is created
A monopolist produces where marginal revenue equals marginal cost (MR = MC), not where price equals marginal cost (P = MC). Because its marginal revenue sits below the price it charges, the firm stops producing while there are still buyers who value the next unit above what it costs to make. Those buyers are willing to pay more than $4; the firm could make the pill for $4; the trade would benefit both sides. It still doesn't happen, because serving those additional buyers would force the price down on everyone else the firm is already selling to.
Every one of those un-made trades had value: the buyer's willingness to pay, minus the cost to produce. Stack up all the value from the monopoly quantity to the competitive quantity, and that sum is the deadweight loss. Visually it is the famous deadweight loss triangle wedged between the demand curve and the marginal-cost curve, over the range of output the monopolist refuses to produce. The triangle is not a metaphor. It represents real things people wanted and were willing to pay for, that never got made.
Running the numbers
Let's use a clean case. Marginal cost is a flat $4 per unit. Demand falls by $2 in price for every additional 1,000 units sold, starting from a price of $40 when quantity is zero.
Under competition, price is driven to marginal cost: $4. At $4, buyers want 18,000 units. Every trade worth making gets made.
A monopolist instead finds where marginal revenue equals the $4 cost. With a straight-line demand curve, marginal revenue falls twice as steeply as demand, so MR hits $4 at 9,000 units, exactly half the competitive quantity. The monopolist sells 9,000 units and reads the price off the demand curve at that point: $22.
So the monopoly produces 9,000 units at $22 versus the competitive 18,000 units at $4. Now tally the deadweight loss across the 9,000 units that go unproduced. On the unit just past the monopoly quantity, a buyer valued it at $22 while it cost $4 to make: roughly $18 of value lost on that trade alone. On the last unproduced unit, the buyer valued it at $4, exactly its cost, so zero value was lost there. Across the missing 9,000 units, the lost value averages roughly half of $18.
That $81,000 is not the monopolist's profit and not the buyers' overpayment. It is gone. The transfer (customers paying $22 instead of $4 on the units that do sell) is a separate, larger number that at least lands in someone's pocket. Deadweight loss lands nowhere.
The same lens, everywhere
The power of this concept is that it is one tool, reused. Anything that wedges price apart from marginal cost, anything that blocks trades both sides would accept, creates deadweight loss. A tax drives a gap between what buyers pay and what sellers receive, and the trades that fall through that gap are deadweight loss. A price ceiling set below the market level causes shortages and lost trades. A tariff or import quota does the same to international exchange.
In every case the question is identical: how much mutually beneficial trade did this prevent? The Federal Trade Commission's case against price-fixing cartels rests on exactly this logic.3 Colluding firms mimic a monopoly, restrict output, and destroy the same triangle of value as a single dominant seller would. The Department of Justice's framework for single-firm conduct under Section 2 of the Sherman Act reaches the same conclusion from a different angle: market power is harmful in proportion to how much it distorts output away from the competitive level.4
Shift to the macroeconomy and the same arithmetic scales up. The Bureau of Economic Analysis tracks gross domestic product (GDP), the total value of goods and services produced.5 Every time a market distortion kills trades, it is shaving something off that figure, not dramatically in any single case, but persistently across an economy with thousands of concentrated markets. The number in your GDP report is the economy that showed up. Deadweight loss is a count of the economy that didn't.
Where the model breaks down
Deadweight loss is a sharp tool aimed at a fuzzy world, and honesty requires naming its limits.
First, it assumes you can measure willingness to pay and marginal cost precisely. In reality both are estimates, and the triangle is only as trustworthy as the curves you draw. The EconLib's entry on antitrust enforcement is candid about this: quantifying market harm requires assumptions about demand elasticity that are genuinely contested among economists.6
Second, the static picture ignores dynamic gains. A patent grants a temporary, deliberate monopoly, and yes, it creates deadweight loss while it lasts. But the prospect of that monopoly profit is what funded the research to invent the drug in the first place. The Department of Justice acknowledges this directly: some market power is the reward that drives innovation, and policy has to weigh today's deadweight loss against tomorrow's inventions that would not exist without it.4 The triangle measures the cost of restricted output in a single moment. It does not, by itself, tell you whether the restriction was worth allowing.
Third, surplus says nothing about who gets the value. It treats a dollar to a billionaire and a dollar to a struggling family identically. Deadweight loss is a measure of efficiency, not of fairness, and the two questions deserve separate tools.
Overall, the takeaway is a habit of mind. Whenever a price sits visibly above the cost of making one more unit, ask the deadweight-loss question: what trades is this gap quietly killing? The answer is a cost that never shows up on anyone's balance sheet. That is exactly why it is so easy to overlook, and so worth training yourself to see.
◆ Sources
- Daraprim Price Increase and Specialty Drug Pricing — U.S. Senate Special Committee on Aging
- Monopoly — Library of Economics and Liberty
- Price Fixing — Federal Trade Commission, Guide to Antitrust Laws
- Competition and Monopoly: Single-Firm Conduct Under Section 2 of the Sherman Act — U.S. Department of Justice, Antitrust Division
- Gross Domestic Product, Third Estimate — U.S. Bureau of Economic Analysis
- Antitrust — Library of Economics and Liberty





